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Available online 8 March 2016AbstractPurpose: To evaluate the frequency of 12 single nucleotide polymorphisms (SNPs) of complement factor H (CFH) and LOC387715/ARMS2/
HRTA1 and their association with some of the presenting clinical features of neovascular age-related macular degeneration (AMD).
Methods: In this prospective non-comparative case series forty four naïve patients with neovascular AMD were genotyped using sequencing or
Sequenom iPLEX technology. Descriptive tests were used for displaying the magnitude of each allele, gender distribution, and age at diagnosis.
Fisher exact test was used to evaluate the correlation between visual acuity (VA) and different alleles. Also Kruskal-Wallis test was used for
comparison between age at the time of diagnosis and different alleles.
Results: The most frequent SNP among studied patients was rs1061147 with 100% frequency rate. The least common was rs2672598 with a
frequency of 52.27%. Only the allele rs800292 of CFH locus on 1q32 was associated with VA better than 20/200 (p value ¼ 0.034). The
frequency of this allele was 77.27% (34 patients) in this study. There was no significant association between any of alleles, and VA worse than
20/200(p > 0.05). Fifteen patients had bilateral exudative AMD (34.09%). There was no significant difference between alleles in bilateral
neovascular AMD and unilateral disease. Also bilateral and unilateral patients were not different in terms of age, gender or VA (p value: 0.330,
0.764 and 0.456 respectively). There was also no significant association between any of SNPs and bilaterality of disease.
Conclusion: We designated the frequencies of SNPs of CFH and LOC387715/ARMS2/HRTA1 in neovascular AMD in a sample of Iranian
patients. Only the allele rs800292 of CFH locus on chromosome 1q32 was associated with better VA.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Age-related macular degeneration (AMD) is the leading
cause of severe central visual loss in the elderly.1,2 Its preva-
lence is estimated to be 13%e29.7% in people over 55 years.3
One of the main reasons of visual loss in AMD is choroidal* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).neovascularization (CNV),4 which occurs in the neovascular
form of the disease. Consequently, most available treatment
modalities are directed against this advanced neovascular
stage of disease.5,6
In addition towell-known risk factors such as aging, smoking,
sunlight exposure, and family history,7,8 many authors have
addressed the role of genetics and special alleles in the patho-
genesis of AMD as well as its clinical features.9 Identification of
exact genes and their either offensive or protective role in this
disease can clearly alter the therapeutic approaches for AMD.osting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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and several adjacent alleles on 10q26 (loc387715/ARMS2
gene and HtrA serine peptidase 1 gene) have been reported to
be strongly associated with neovascular AMD. There are also
some conflicting reports about the association of these alleles
and some clinical and angiographic features of AMD.7e19
In this study, we investigated the frequency of some of the
previously reported alleles associated with neovascular AMD
as well as the association between these alleles and clinical
features of AMD.
Methods
We enrolled 44 patients who were referred to the Retina
Service of Farabi Eye Hospital of Tehran University of
Medical Sciences (TUMS) between February to April 2014.
The study protocol was approved by the review board of
Farabi Eye Hospital and the Committee of Medical Ethics of
TUMS. Moreover, informed written consent was obtained
from all patients.
After recording demographic data (age at the time of
diagnosis, gender, family history) and patient medical history,
a complete bilateral ophthalmic examination was performed
for each patient as follows: examining best corrected visual
acuity (BCVA) (using snellen chart and then converting it to
logMAR), anterior segment examination, intraocular pressure
measurement, and full dilated fundoscopy. The inclusion
criteria were presence of neovascular AMD at least in one eye
which was defined by having CNV, subretinal hemorrhage,
fibrosis, and angiographic documentation of the CNV at the
time of diagnosis (using Heidelberg fluorescein angiography)
or before entering the study. All the patients with suspicious
polypoidal choroidal vasculopathy and retinal angiomatous
proliferation were evaluated by indocyanine green (ICG)
angiography and excluded from the study if the diagnosis
was confirmed. Patients with pathologic myopia, angioid
streaks, choroidal rupture, any history of retinal laser
treatment, or any disease condition other than AMD which
can cause CNV and any history of intravitreal pharmacologic
injection treatment were excluded. All patients were
treatment naïve and no previous treatment had been
performed.
Presence of dry or wet type AMD in the other eye was also
recorded. In patients with bilateral neovascular involvement,
the eye with a worse clinical state was chosen for statistical
analysis. All the patients or their information profile including
fluorescein angiography were reviewed at least by 2 retinal sub
specialists.Genetic analysis15 ml of peripheral blood samples from each 44 of the
patients nAMD was collected by antecubital venipuncture into
ethylenediaminetetraacetic acid (EDTA)-containing tubes.
After adding 10 ml of Red Cell Lysis Buffer and mixing
completely, samples were centrifuged for 10 min at 1,300 g
(3e30k Refrigerated Centrifuge, Sigma, Germany). Afterdiscarding supernatant and adding 10 ml Phosphate Buffered
Salts (PBS Tablets; TAKARA BIO INC., Japan), cell pellets
were suspended again and centrifuged for 8 min at 1,200 g for
washing, twice.
Harvested Cells were used for genomic DNA extraction
with a DNA blood kit (QIAamp® DNA Blood Mini kit; Qia-
gen, Germany) according to the manufacturer's protocol
(which was briefly, 20 ml proteinase K was added to the 200 ml
of cells plus 200 ml lysis buffer. After adding 200 ml ethanol
and vortexing, samples were transferred to the columns and
centrifuged at 6000 g for 1 min. Then 500 ml washing buffer
was added and centrifuged at 20,000 g for 3 min. Finally,
20 ng of purified DNAwas used for genotyping analysis). For
genetic analysis Sequenom iPLEX system technology was
used (Sequenom, San Diego, CA, USA) to detect AMD related
SNPs in the following order: rs203674, rs800292, rs35507625,
rs572515, rs1061147, rs7529589, rs1061170, rs12038333,
rs2274700, for CFH gene on chromosome 1 and rs10664316,
rs11200638, rs2672598 for LOC387715/ARMS2/HTRA1
gene on chromosome 10.Statistical analysisStatistical analysis was performed using SPSS 16 software
(SPSS, Inc., Chicago,IL). Prescriptive tests were used for
displaying the magnitude of each allele, gender distribution,
and age (mean ± SD). Visual acuities were converted to the
logarithm of the minimal angle of resolution (logMAR) units
and were categorized into 2 groups: logMAR1 (snellen
acuity  20/200) as better visual acuity (VA) and logMAR>1
(snellen visual acuity <20/200) as worse VA. Fisher exact test
used to evaluate the correlation between VA and different al-
leles. KruskaleWallis test was also used for comparison be-
tween age at the time of diagnosis and different alleles.
p < 0.05 was considered statistically significant. The associ-
ation between SNPs and age groups (equal or less than 75
years old versus more than 75 years old), sex, and laterality
(disease affecting one eye or both eyes of the patients) have
been assessed by using chi square test. The HardyeWeinberg
Equilibrium was calculated for each SNP, and all the SNPs
were in HardyeWeinberg Equilibrium.
Results
44 eligible patients entered the study. 28 patients were male
(63.6%), and 16 patients were female (36.4%). The mean age
of patients was 74.63 ± 7.55 years (ranged from 58 to 90
years). Mean VA of patients was 1.7 ± 0.8 logMAR. The
frequencies of all SNPs among patients are detailed in Table 1.
The most frequent SNP among study patients was rs1061147
with 100% frequency. The least common was rs2672598 with
a frequency of 52.27%.
Only the allele rs800292 of CFH locus on 1q32 was asso-
ciated with VA better than 20/200 (p value ¼ 0.034). Mean VA
of the patients with this allele was 0.1 ± 0.12 logMAR. The
frequency of this allele was 77.27% (34 patients). There was
Table 1
Statistical association of each SNP with age, sex,VA, and laterality.
Gene SNP Age (75 years vs > 75 years)
(p value)
Sex (p value) Better VA (better than
20/200) (p value)
Laterality (bilateral or
unilateral) (p value)
CFH rs203674 0.994 0.265 0.513 0.330
CFH rs572515 0.820 0.561 0.773 0.456
CFH rs800292 0.590 0.886 0.034 0.764
CFH rs1061147 0.800 0.977 0.444 0.822
CFH rs1061170 0.378 0.820 0.435 0.424
CFH rs2274700 0.555 0.197 0.772 0.672
CFH rs7529589 0.424 0.539 0.591 0.515
CFH rs12038333 0.185 0.208 0.247 0.522
CFH rs35507625 0.985 0.892 0.326 0.342
LOC387715/ARMS2 rs11200638 0.672 0.472 0.262 0.635
LOC387715/ARMS2 rs10664316 0.966 0.773 0.342 0.514
HTRA1 rs2672598 0.633 0.680 0.355 0.625
SNP: single nucleotide polymorphisms, VA: visual acuity, CFH: complement factor H, ARMS2: age related maculopathy susceptibility 2 gene, HTRA1: HtrA
serine peptidase 1 gene.
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than 20/200.
Fifteen patients had bilateral neovascular AMD (34.09%).
There was no significant difference between allele frequencies
between bilateral and unilateral AMD groups.
Discussion
AMD is one of the most common causes of blindness in the
elderly worldwide. Multiple risk factors have been proposed in
the pathogenesis of this disease. The role of genetic factors in
the etiology of AMD is documented, and several predisposing
SNPs have been proposed to be associated with AMD
(Table 3).7e30 The most important SNPs are CFH gene on
chromosome 1 and LOC387715/ARMS2/HTRA1 on chro-
mosome 10.11e17,23 CFH gene expression affects the binding
affinity of CFH glycoprotein to C-reactive protein and heparin
and regulates its anti-inflammatory effects.17 The exact
mechanism of action of the LOC387715 gene product is not
clearly understood.29 Allele frequency of these genes wasTable 2
Single nucleotide polymorphism analyzed in 44 nonvascular AMD patients.
Gene SNP Base changea Total frequency (%
CFH rs203674 C/A 90.90%
CFH rs572515 T/C 93.18%
CFH rs800292 C/A 77.27%
CFH rs1061147 A/C 100%
CFH rs1061170 C/T 70.45%
CFH rs2274700 C/T 95.45%
CFH rs7529589 T/C 88.63%
CFH rs12038333 G/A 90.90%
CFH rs35507625 del 93.18%
LOC387715/ARMS2 rs11200638 A/G 63.63%
LOC387715/ARMS2 rs10664316 Del AT 86.36%
HTRA1 rs2672598 G/A 52.27%
CFH ¼ complement factor H gene, ARMS2 ¼ age-related maculopathy susceptibi
polymorphism.
a Base change is written common allele > rare allele.between 61 and 94% in AMD patients in some stud-
ies.9,12e18,24 However, the frequency is not constant across
different ethnic groups. In some reports of Chinese and
Turkish population samples, the frequencies are lower than
what has been reported in other ethnic groups, especially
Caucasians.23,28 In this study, the frequencies of some of the
previously reported SNPs in neovascular AMD patients were
evaluated in a sample of an Iranian population.
In our case series, rs1061147 from CFH genes on 1q32 was
the most common allele (100% frequency rate), and the least
common SNP was rs2672598 from loc387715/ARMS2/
HTRA1 on 10 q26 (frequency rate: 52.27%). All the other
SNPs' frequencies ranged from 52.27% to 99.9% (Table 2).
These frequencies are consistent with some of the previous
studies that reported similar findings in their own ethnic
populations.9,12e18,24 In the Andreoli cohort study, similar
frequencies for both CFH and LOC-387715/ARMS2/HRTA1
SNPs9 were found. However, in some other ethnic pop-
ulations, the reported frequencies were different. For example,
Chen et al. reported a frequency of 5.8% for CFH genes in) Frequency of homozygous
common allele
Frequency of
heterozygous allele
Frequency of
homozygous
rare allele
0.365 0.414 0.219
0.341 0.414 0.243
0.735 0.26 0
0.509 0.372 0.117
0.387 0.483 0.129
0.547 0.285 0.166
0.358 0.512 0.128
0.35 0.45 0.2
0.829 0.121 0.04
0.5 0.357 0.142
0.552 0.342 0.105
0.565 0.434 0
lity 2 gene, HTRA1 ¼ HtrA serine peptidase 1 gene, SNP ¼ single nucleotide
Table 3
Effect of SNPs on clinical findings of AMD patients in different studies.
Year Author Countery Study design Mean age Male/female
ratio
Earlier age
of onset
Better visual
acuity
(better than
20/200)
Worse visual
acuity
Bilateral
involvement
Larger
CNV size
2014 This study Iran Case series 74.63 ± 7.55 63.6%/36.4% Non rs800292 Non Non Non
2009 Andreoli9 USA Retrospective
cohort
72.5 ± 7.8 46.4%/53.6% rs11200638
and rs10490924
rs10664316
and
rs1049331
Non Non rs11200638
2011 Hiroaki
Bessho31
Japan Retrospective
cohort
76 ± 6 85.4%/14.6 Non Non Non Non rs10490924
2008 Leveziel N19 France Cohort 72.8 ± 8.8 32%/68% rs11200638
and rs10490924
Non Non Non Non
2007 Brantley MA20 USA Retrospective
cohort
79.8 36%/64% rs11200638
and rs10490924
Non Non Non rs1061170
2009 Brantle MA21 USA Case-control 78.9 ± 8.1 35.6%/64.8% rs11200638
and rs10490924
Non Non Non Non
2008 Shuler RK22 USA Case-control 76.4 33.6%/66.4% rs11200638
and rs10490924
Non Non Non Non
2011 Chen H32 USA Cohort 75.1 ± 9.0 46.4%/53.6% Non Non Non rs11200638/rs
10490924
Non
2009 Pai AS27 Australia Cross-sectional 73.9 ± 8.3/
80.4 ± 7.9
34.6%/65.4% Non Non Non CFH CC
genes
Non
2007 Shuler RK30 USA Cross-sectional 75.8 ± 8.6 44.2%/55.8% rs10490924
and CFH
(T1277C at
rs1061170,
or Y402H)
Non Non Non Non
2010 Nicolas
Leveziel33
France Cohort 80.6 ± 5.8 33.4%/66.6% Non Non rs10490924
pp/rs10611710
pp
rs10490924
pp/rs10611710
pp
Non
SNP: single nucleotide polymorphisms, AMD: age related macular degeneration, CNV: choroidal neovascularization, CFH: complement factor H.
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Babanejad et al.25 reported the same frequency for rs800292 C
allele, but the reported frequencies for rs2274700 and
rs1061170 (either C allele, rare allele and heterozygous allele)
was different from our study. Additionally, in Nazari Khana-
miri et al.’s caseecontrol study,24 Y402H and A69S poly-
morphisms were strongly associated with AMD in a sample of
the Iranian population.24
Among 12 alleles assessed in this study, only rs800292 of
CFH SNPs was associated with VA better than 20/20 (p value
0.034). This is not in accordance with previously published
results by Andreoli et al.9 which found LOC387715/ARMS2
rs10664316 and HTRA1 rs1049331 as the SNPs which were
associated with protection from worse visual acuity at the time
of diagnosis.
We also did not find any association between assessed al-
leles and age or gender. Some studies reported rs11200638 and
rs10490924 from LOC387715/ARMS2 to be associated with
earlier age of onset of AMD.9,19e23
In this case series, there was no difference between uni-
lateral or bilateral involvement considering SNP frequencies,
but it has been reported in previous trials that CFH genes also
rs11200638 cause susceptibility to bilateral AMD involvement
26,27.
This is one of the few studies which has evaluated AMD
genetics in an Iranian population.24, 25 Limitations of this
study include a lack of a control group and small sample size.In conclusion, AMD seems to have a strong genetic
pathogenesis which may influence its clinical features.
Further studies which include a larger sample size, a
control group, and careful follow-up will clarify more de-
tails of this multifactorial prevalent disease pathogenesis.
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